CpG ODN, Toll like receptor (TLR)-9 agonist, inhibits metastatic colon adenocarcinoma in a murine hepatic tumor model

Journal of Surgical Research

Volumn 174, Issue 2, 2012, Pages 284-290

  Kim, Ik Yong ^c   Yan, Xiaohong ^a   Tohme, Samer ^a   Ahmed, Aqeel ^b   Cordon Cardo, Carlos ^b   Shantha Kumara, H M C ^a   Kim, Soo Ki ^c   Whelan, Richard L ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Yonsei University Wonju   (South Korea)

Author keywords

colon cancer; CpG oligodeoxynucleotide (CpG); liver metastasis; toll like receptor (TLR) 9

Indexed keywords

ANTINEOPLASTIC AGENT; CPG OLIGODEOXYNUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLON ADENOCARCINOMA; CONTROLLED STUDY; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIVER METASTASIS; LYMPHOCYTIC INFILTRATION; MITOSIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; COLONIC NEOPLASMS; CPG ISLANDS; FEMALE; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; ORGAN SIZE; PORTAL VEIN; TOLL-LIKE RECEPTOR 9;

EID: 84859522363     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2010.12.021     Document Type: Article

References (37)

1. Bird NC, Mangnall D, Majeed AW. Biology of colorectal liver metastases: A review. J Surg Oncol 2006;94:68.
2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476.
3. Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: A prospective study of medical and economic benefits. Vaccine 2005;23:2379.
4. Heys SD, Deehan DJ, Eremin O. Interleukin-2 treatment in colorectal cancer: Current results and future prospects. Eur J Surg Oncol 1994;20:622.
5. Hill ADK, Redmond HP, Naama HA, et al. Granulocyte-macrophage colony-stimulating factor inhibits tumor growth during the postoperative period. Surgery 1996;119:178.
6. Carter JJ, Feingold DL, Wildbrett P, et al. Significant reduction of laparotomy-associated lung metastases and subcutaneous tumors after perioperative immunomodulation with flt3 ligand in mice. Surg Innov 2005;12:319.
7. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197.
8. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740.
9. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: Up-regulation of TLR-9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003;101:4500.
10. Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophils function. Blood 2003;102:2660.
11. Saikh KU, Kissner TL, Sultana A, et al. Human monocytes infected with Yersinia pestis express cell surface TLR-9 and differentiate into dendritic cells. J Immunol 2004;173:7426.
12. Gelman AE, LaRosa DF, Zhang J, et al. The adaptormolecule-MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide- mediated costimulation. Immunity 2006;25:783.
13. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 2003;300:1524.
14. Tsujimura H, Tamura T, Kong HJ, et al. Toll-like receptor 9 signaling activates NF-κB through IFN regulatory factor- 8/IFN consensus sequence binding protein in dendritic cells. J Immunol 2004;172:6820.
15. Yang K, Puel A, Zhang S, et al. Human TLR-7, -8, and -9 mediated induction of IFN-α/β and -λ is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 2005;23:465-78. (Pubitemid 41587887)
16. Klinman DM, Yi AK, Beaucage SL, et al. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996;93:2879.
17. Yi AK, Chace JH, Cowdery JS, et al. IFN-γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol 1996;156:558.
18. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471.
19. Krieg AM. The role of CpG motifs in innate immunity. Curr Opin Immunol 2000;12:35.
20. Maurer T, Heit A, Hochrein H, et al. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol 2002;32:2356.
21. Warren TL, Bhatia SK, Acosta AM, et al. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol 2000;165:6244.
22. Carpentier AF, Chen L, Maltonti F, et al. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999;59:5429.
23. Carpentier AF, Xie J, Mokhtari K, et al. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 2000;6:2469.
24. Heckelsmiller K, Rall K, Beck S, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002;169:3892.
25. Lonsdorf AS, Kuekrek H, Stern BV, et al. Intratumor CpG- oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 2003;171:3941.
26. Kawarada Y, Ganss R, Garbi N, et al. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001;167:5247.
27. Krieg AM. Toll like receptor 9 (TLR-9) agonists in the treatment of cancer. Oncogene 2008;27:161.
28. Link BK, Ballas ZK, Weisdorf D, et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 2006;29:558.
29. Carpentier A, Laigle-Donadey F, Zohar S, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncology 2006;8:60.
30. Manegold C, Gravenor D, Woytowitz D, et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3979.
31. Pashenkov M, Goess G, Wagner C, et al. Phase II trial of a toll-like receptor 9 activating oligodeoxynucleotide in patients with metastatic melanoma. J Clin Oncol 2006;24:5716.
32. Krieg AM. Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004;6:88.
33. Georges C, Lo T, Alkofer B, et al. The effects of surgical trauma on colorectal liver metastasis. Surg Endosc 2007;21:1817.
34. Jahrsdorfer B, Wooldridge JE, Blackwell SE, et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005;77:378.
35. Shantha Kumara HMC, Feingold D, Kalady M, et al. Colorectal resection is associated with persistent proangiogenic plasma protein changes: Postoperative plasma stimulates in vitro endothelial cell growth, migration, and invasion.AnnSurg 2009;249:973.
36. Kirman I, Belizon A, Balik E, et al. Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing surgery. Eur J Surg Oncol 2007;33:1169.
37. Wu FP, Westphal JR, Hoekman K, et al. The effects of surgery, with or without rhGM-CSF, on the angiogenic profile of patients treated for colorectal carcinoma. Cytokine 2004;25:68.